1
|
Sakahashi Y, Higashisaka K, Izutani R, Seo J, Kitahara G, Kobayashi J, Nakamoto Y, Yamamoto R, Tsujino H, Haga Y, Tsutsumi Y. P06-02 Silver nanoparticles inhibit intercellular fusion in the BeWo syncytialization process. Toxicol Lett 2022. [DOI: 10.1016/j.toxlet.2022.07.320] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
2
|
Yang L, Higashisaka K, Haga Y, Tsujino H, Nagano K, Tsutsumi Y. Alpha-crystallin B chains enhance cell migration in basal-like 2 triple-negative breast cancer cells. Pharmazie 2022; 77:45-47. [PMID: 35209962 DOI: 10.1691/ph.2022.11019] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Triple-negative breast cancer (TNBC) can be divided into six subtypes. Among these subtypes, the basal-like 2 (BL2) subtype shows the lowest five-year survival rate and highest risk of metastasis. Alpha-crystallin B chains (αB-crystallin), a small heat shock protein that is known to be involved in breast cancer metastasis, is highly expressed in the basal-like subtype but not in the other non-basal subtypes. Thus, we hypothesized that αB-crystallin may be an important factor involved in the worse prognosis of the BL2 subtype compared with those of the other TNBC subtypes. Here, we examined the role of αB-crystallin in cell motility in two TNBC cell lines: HCC1806 (BL2 subtype) and, as control, MDA-MB-436 (mesenchymal stem-like subtype). HCC1806 showed greater cell migration capacity and a higher expression level of the gene encoding αB-crystallin (CRYAB) than did MDA-MB-436. Short interfering RNA-mediated silencing of CRYAB expression significantly reduced the cell migration capacity of HCC1806 cells, whereas it had no effect in MDA-MB-436 cells, indicating that αB-crystallin is essential for the migration of HCC1806 cells. Thus, high αB-crystallin expression may be a contributing factor to the poor prognosis of BL2 TNBC.
Collapse
Affiliation(s)
- L Yang
- Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan
| | - K Higashisaka
- Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan; Institute for Advanced Co-Creation Studies, Osaka University, Osaka, Japan;,
| | - Y Haga
- Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan
| | - H Tsujino
- Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan; The Museum of Osaka University, Osaka, Japan
| | - K Nagano
- Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan; School of Pharmaceutical Sciences, Wakayama Medical University, Wakayama
| | - Y Tsutsumi
- Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan; Global Center for Medical Engineering and Informatics, Osaka University, Osaka, Japan;,
| |
Collapse
|
3
|
Hanamuro S, Lin Y, Konishi H, Izusawa K, Yang L, Haga Y, Tsujino H, Nagano K, Higashisaka K, Tsutsumi Y. Progesterone receptor membrane component 2 expression leads to erlotinib resistance in lung adenocarcinoma cells. Pharmazie 2021; 76:602-605. [PMID: 34986956 DOI: 10.1691/ph.2021.1775] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) provide a favorable treatment outcome in patients with EGFR mutation-positive non-small cell lung cancer. However, most of such patients become resistant to EGFR-TKIs within a year. Thus, clarifying the mechanism of acquired resistance to EGFR-TKIs has been a research focus. Here, we demonstrated that the expression of progesterone receptor membrane component 2 (PGRMC2) was upregulated in an erlotinib-resistant cell line, PC9/ER, compared with the parental PC9 lung cancer cells. Our previous study showed that PGRMC1 is responsible for acquired resistance to erlotinib; however, PGRMC2 has not been discussed yet. Thus, the aim of this study was to determine the role of PGRMC2 in acquired resistance to erlotinib. Transfection with PGRMC2 siRNA significantly enhanced the sensitivity to erlotinib in PC9/ER cells. Furthermore, knockdown of PGRMC2 reduced the expression of p21, which is known as cell-cycle inhibitor and antiproliferative effector. These results suggest that PGRMC2 partially contributes to erlotinib resistance in PC9/ER cells, and that investigation into the effect of PGRMC2 on apoptosis and the cell cycle are warranted.
Collapse
Affiliation(s)
- S Hanamuro
- Laboratory of Toxicology and Safety Science, Osaka, Japan
| | - Y Lin
- Laboratory of Toxicology and Safety Science, Osaka, Japan
| | - H Konishi
- Laboratory of Toxicology and Safety Science, Osaka, Japan
| | - K Izusawa
- Laboratory of Toxicology and Safety Science, Osaka, Japan
| | - L Yang
- Laboratory of Toxicology and Safety Science, Osaka, Japan
| | - Y Haga
- Laboratory of Toxicology and Safety Science, Osaka, Japan
| | - H Tsujino
- Laboratory of Toxicology and Safety Science, Osaka, Japan; Graduate School of Pharmaceutical Sciences, Osaka University; The Museum of Osaka University, Osaka, Osaka, Japan
| | - K Nagano
- Laboratory of Toxicology and Safety Science, Osaka, Japan; School of Pharmaceutical Sciences, Wakayama Medical University, Wakayama, Osaka, Japan
| | - K Higashisaka
- Laboratory of Toxicology and Safety Science, Osaka, Japan; Institute for Advanced Co-Creation Studies, Osaka University, Osaka, Japan;,
| | - Y Tsutsumi
- Laboratory of Toxicology and Safety Science, Osaka, Japan; Global Center for Medical Engineering and Informatics, Osaka University, Osaka, Japan;,
| |
Collapse
|
4
|
Yamashita T, Kamada H, Kanasaki S, Nagano K, Inoue M, Higashisaka K, Yoshioka Y, Tsutsumi Y, Tsunoda S. Ephrin type-A receptor 2 on tumor-derived exosomes enhances angiogenesis through the activation of MAPK signaling. Pharmazie 2019; 74:614-619. [PMID: 31685088 DOI: 10.1691/ph.2019.9474] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 09/29/2022]
Abstract
Exosomes are potent players in the development of metastases and they play an important role in cancer angiogenesis and exacerbation. However, it is unclear how proteins on exosomes affect development of blood vessel networks. In this study, we focused on relationships between membrane proteins on exosomes and angiogenesis using human umbilical vein endothelial cells (HUVEC). Lung tumor cell-derived exosomes induced tube formation and growth of endothelial cells in vitro in a dose-dependent manner involving MAPK activation, but this was not seen in normal lung epithelial cells. Ephrin type-A receptor 2 (EphA2) was identified by proteomic analysis and an inhibition assays showed it is a major MAPK activator on exosomes. Thus EphA2 on exosomes participates in angiogenesis as a ligand of the ephrin signaling pathway. These results support the development of novel therapeutic strategies such as blockade of remote cancer communications through exosomes.
Collapse
|
5
|
Hirai T, Yoshioka Y, Takahashi H, Handa T, Izumi N, Mori T, Uemura E, Nishijima N, Sagami K, Yamaguchi M, Eto S, Nagano K, Kamada H, Tsunoda S, Ishii KJ, Higashisaka K, Tsutsumi Y. High-dose cutaneous exposure to mite allergen induces IgG-mediated protection against anaphylaxis. Clin Exp Allergy 2016; 46:992-1003. [DOI: 10.1111/cea.12722] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2015] [Revised: 01/18/2016] [Accepted: 02/07/2016] [Indexed: 11/30/2022]
Affiliation(s)
- T. Hirai
- Laboratory of Toxicology and Safety Science; Graduate School of Pharmaceutical Sciences; Osaka University; Osaka Japan
| | - Y. Yoshioka
- Laboratory of Toxicology and Safety Science; Graduate School of Pharmaceutical Sciences; Osaka University; Osaka Japan
- Vaccine Creation Project; BIKEN Innovative Vaccine Research Alliance Laboratories; Research Institute for Microbial Diseases; Osaka University; Osaka Japan
- BIKEN Center for Innovative Vaccine Research and Development; The Research Foundation for Microbial Diseases of Osaka University; Osaka Japan
| | - H. Takahashi
- Laboratory of Toxicology and Safety Science; Graduate School of Pharmaceutical Sciences; Osaka University; Osaka Japan
- Vaccine Creation Project; BIKEN Innovative Vaccine Research Alliance Laboratories; Research Institute for Microbial Diseases; Osaka University; Osaka Japan
| | - T. Handa
- Laboratory of Toxicology and Safety Science; Graduate School of Pharmaceutical Sciences; Osaka University; Osaka Japan
| | - N. Izumi
- Laboratory of Toxicology and Safety Science; Graduate School of Pharmaceutical Sciences; Osaka University; Osaka Japan
| | - T. Mori
- Laboratory of Innovative Antibody Engineering and Design; Center for Drug Innovation and Screening; National Institutes of Biomedical Innovation; Health and Nutrition; Osaka Japan
| | - E. Uemura
- Laboratory of Toxicology and Safety Science; Graduate School of Pharmaceutical Sciences; Osaka University; Osaka Japan
| | - N. Nishijima
- Laboratory of Toxicology and Safety Science; Graduate School of Pharmaceutical Sciences; Osaka University; Osaka Japan
| | - K. Sagami
- Laboratory of Toxicology and Safety Science; Graduate School of Pharmaceutical Sciences; Osaka University; Osaka Japan
| | - M. Yamaguchi
- Laboratory of Toxicology and Safety Science; Graduate School of Pharmaceutical Sciences; Osaka University; Osaka Japan
| | - S. Eto
- Laboratory of Toxicology and Safety Science; Graduate School of Pharmaceutical Sciences; Osaka University; Osaka Japan
| | - K. Nagano
- Laboratory of Biopharmaceutical Research; National Institutes of Biomedical Innovation; Health and Nutrition; Osaka Japan
| | - H. Kamada
- Laboratory of Biopharmaceutical Research; National Institutes of Biomedical Innovation; Health and Nutrition; Osaka Japan
- The Center for Advanced Medical Engineering and Informatics; Osaka University; Osaka Japan
| | - S. Tsunoda
- Laboratory of Biopharmaceutical Research; National Institutes of Biomedical Innovation; Health and Nutrition; Osaka Japan
- The Center for Advanced Medical Engineering and Informatics; Osaka University; Osaka Japan
| | - K. J. Ishii
- Laboratory of Adjuvant Innovation; National Institutes of Biomedical Innovation; Health and Nutrition; Osaka Japan
- Laboratory of Vaccine Science; Immunology Frontier Research Center; World Premier International Research Center; Osaka University; Osaka Japan
| | - K. Higashisaka
- Laboratory of Toxicology and Safety Science; Graduate School of Pharmaceutical Sciences; Osaka University; Osaka Japan
| | - Y. Tsutsumi
- Laboratory of Toxicology and Safety Science; Graduate School of Pharmaceutical Sciences; Osaka University; Osaka Japan
- Laboratory of Innovative Antibody Engineering and Design; Center for Drug Innovation and Screening; National Institutes of Biomedical Innovation; Health and Nutrition; Osaka Japan
- The Center for Advanced Medical Engineering and Informatics; Osaka University; Osaka Japan
| |
Collapse
|
6
|
Nagano T, Yoshioka Y, Higashisaka K, Kunieda A, Hata K, Nagano K, Abe Y, Kamada H, Tsunoda S, Nabeshi H, Yoshikawa T, Tsutsumi Y. Potential of acute-phase proteins as biomarkers for sub-nano platinum exposure. Pharmazie 2012; 67:958-959. [PMID: 23210250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Affiliation(s)
- T Nagano
- Laboratory of Toxicology and Safety Science, Graduate School of Pharmaceutical Sciences, Osaka University, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Higashisaka K, Yoshioka Y, Yamashita K, Morishita Y, Nabeshi H, Tsunoda S, Itoh N, Tsutsumi Y. Development of biomarkers for ensuring safety of nanomaterials. Toxicol Lett 2011. [DOI: 10.1016/j.toxlet.2011.05.248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|